Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

LBH 2022 > MABs > Flashcards

MABs Flashcards

1
Q

Adalimumab

A

Anti-TNF

Rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Afatinib

A

TK inhibitor - EGFR, ERBB2, ERBB4

NSCLC (EGFR mutation +ve excluding T790M)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Alemtuzumab

A

Anti-CD52 (Humanised IgG1)

CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Anakinra

A

IL1 blockade

Rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Axitinib

A

TK inhibitor - VEGFR1/2/3, PDGFRb, c-KIT

RCC (2nd line)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Basiliximab

A

Anti-IL2R

Transplant
Anti-CD25

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Belatacept

A

T cell co-stimulation blocker (Fc protein + CTLA4)

Transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Belimumab

A

Anti-BLYs/BAFF
Inhibits B cell proliferation/survival

SLE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Benralizumab

A

Anti-IL5 R alpha

Asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bevacizumab

A

Bevacizumab is a recombinant, humanized monoclonal antibody.
Neturalizes VEGF, preventing its association with endothelial receptors, Flt-1 and KDR

CRC
Ovarian cancer
CNS cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bezlotoxumab

A

Anti-C.diff toxin B

C.diff recurrent infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Blinatumomab

A

Bi-specific T-cell engaging antibody

Acute lymphoblastic leukaemia (relapsed disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bortezomib

A

Proteasome inhibitor
-Inhibit NF-kappa B

Multiple myeloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Brentuximab

A

Anti-CD30 conjugated antibody

Hodgkin’s Disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Brodalumab

A

Anti-17R

Psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Canakinumab

A

Anti-IL1b

Rheumatoid arthritis
Autoinflammatory disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Certolizumab pegol

A

Anti-TNF

Crohn’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cetuximab

A

EGFR inhibitor

Head and neck SCC
Metastatic CRC

Must be KRAS Wild Type!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Criznlizumab

A

P-selectin glycoprotein ligand 1

Sickle cell crisis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Crizotinib

A

TK inhibitor - ALK and Ros1 inhibitor

NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Dabrafenib

A

TK inhibitor - BRAF

Melanoma (BRAF V600)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Daclizumab

A

Anti-IL2R

Renal transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Dasatinib

A

TK inhibitor

Bcr-Abl, SRC, c-kit, ephrin receptors

CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Denosumab

A

Denosumab binds to RANKL, blocks the interaction between RANKL and RANK (a receptor located on osteoclast surfaces), and prevents osteoclast formation, leading to decreased bone resorption and increased bone mass in osteoporosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Eculizumab

A

Anti-C5

PNH
aHUS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Efalizumab

A

Anti-CD11a

Psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Eltrombopag

A

Eltrombopag is a thrombopoietin (TPO) nonpeptide agonist which increases platelet counts by binding to and activating the human TPO receptor. Activates intracellular signal transduction pathways to increase proliferation and differentiation of marrow progenitor cells.

ITP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Erlotinib

A

TK inhibitor - EGFR receptor

NSCLC (EGFR Mutation +ve, excluding T790M)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Evolocumab

A

PCSK9 inhibitor

Familial hypercholesterolaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Etanercept

A

TNF blockade

RA
PsA
Ank Spon

31
Q

Gefitinib

A

TK inhibitor - EGFR

NSCLC (EGFR mutation +ve, excluding T790M)

32
Q

Golimumab

A

Anti-TNF

RA
PsA
Ank Spon

33
Q

Ibritumomab tiuxetan

A

Anti-CD20

NHL

34
Q

Ibrutinib

A

BTK inhibitor (B cells)

CLL
Waldenstrom's 
Mantle cell lymphoma
Marginal zone lymphoma
Chronic GVHD
35
Q

Idarucizumab

A

Dabigatran reversal

36
Q

Imatinib

A

TK Inhibitor - BCR-ABL pathway

CML (Ph+)
GIST
ALL (Ph+)

37
Q

Infliximab

A

Anti-TNF

Crohn’s disease

38
Q

Ipilimumab

A

Anti-CTLA4

Metastatic melanoma

39
Q

Ixekizumab

A

Anti-IL17a

Psoriasis

40
Q

Lapatinib

A

TK inhibitor - HER2

HER2+ Breast cancer (2nd line)

41
Q

Mepolizumab

A

Anti-IL5

Asthma

42
Q

Mongersen

A

SMAD7 Antisense olignucleotide

Crohn’s

43
Q

Nataolizumab

A

Anti-a4 integrin

Multiple sclerosis

44
Q

Nilotinib

A

TK Inhibitor - Bcr-Abl kinase

CML
GIST - off label

45
Q

Nintedanib

A

TKI - BEGFR, FGFR

Idiopathic pulmonary fibrosis

46
Q

Nivolumab

A

Anti-PD1

Melanoma

47
Q

Obinutuzumab

Anti-CD20

CLL

A
48
Q

Ofatumumab

Anti-CD20

CLL

A
49
Q

Omalizumab

A

Anti-IgE

Asthma

50
Q

Olaparib

A

TK inhibitor - PARP

BRCA mutated high-grade serious epithelial ovarian ca
Fallopian tube
Primary peritoneal ca

51
Q

Osimmertinib

A

EGFR TKI

NSCLC T790M mutation EGFR gene

52
Q

Palibociclib

A

CDK4/6 inhibitor

ER+ Breast Ca

53
Q

Panitumumab

A

Anti-EGFR

CRC

54
Q

Pazopanib

A

BEGFR1/2/3, PDGFR, KIT

RCC
Sarcoma

55
Q

Pembrolizumab

A

Anti-PD1

Melanoma

Pembrolizumab is a highly selective anti-PD-1 humanized monoclonal antibody which inhibits programmed cell death-1 (PD-1) activity by binding to the PD-1 receptor on T-cells to block PD-1 ligands (PD-L1 and PD-L2) from binding.

56
Q

Peruzumab

A

Anti-HER2/HER3

Extracellular dimerization domain of HER2

57
Q

Ponatinib

A

BCR-ABL1 TKI

58
Q

Quizartinib

A

FLT-3 inhibitor

59
Q

Ramucirumab

A

Anti-VEGF receptor

Gastric ca

60
Q

Reslizumab

A

Anti-CD20

NHL

61
Q

Romosozumab

A

Sclerostin inhibitor

Osteoporosis

62
Q

Ruxolitinib

A

Jak1/2/ inhibitor

Myeloproliferation

63
Q

Secukinumab

A

Anti-IL17a

Psoriasis

64
Q

Siltuximab

A

Anti-IL 6

Castleman disease

65
Q

Sorafenib

A

TK inhibitor - BEGFR2/3, PDGFR, C-Raf> B-raf, KIT

Advanced RCC
Unresectable HCC
Thyroid ca

66
Q

Sunitinib

A

TK inhibitor - FGF, PDGFR, RET, FLT3, VEGFR1/2 receptors, CD 117 (c-KIT) inhibitor

GIST
RCC
Pancreatic neuroendocrine tumours

67
Q

Tocilizumab

A

Anti-IL6R (Humanised IgG1)

RA
GCA

68
Q

Tofacitinib

A

Jak3 inhibitor

RA

69
Q

Tositumomab

A

Anti-CD20

NHL

70
Q

Trastuzumab

A

Anti-HER2 (extracellular)

Metastatic breast ca (HER2+)
GI cancer

71
Q

Ustekinumab

A

Anti-IL12/23

Psoriasis

72
Q

Vedolizumab

A

Anti-a4b7 integrin

UC
CD

73
Q

Vemurafenib

A

TK inhibitor - B-Raf inhibitor

Melanoma (BRAF V600 mutation)

74
Q

Dupilumab

A

Anti- IL4, IL 13

Asthma, moderate to severe eosinophilic or oral glucocorticoid dependent

Atopic dermatitis

Rhinosinusitis (chronic) with nasal polyposis

LBH 2022 (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions